- Home
- RXRX vs IOVA Comparison
RXRX vs IOVA Comparison
Compare RXRX & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RXRX
- IOVA
- Stock Information
- Founded
- RXRX 2013
- IOVA 2007
- Country
- RXRX United States
- IOVA United States
- Employees
- RXRX N/A
- IOVA N/A
- Industry
- RXRX Biotechnology: Pharmaceutical Preparations
- IOVA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RXRX Health Care
- IOVA Health Care
- Exchange
- RXRX Nasdaq
- IOVA Nasdaq
- Market Cap
- RXRX 2.6B
- IOVA 2.6B
- IPO Year
- RXRX 2021
- IOVA N/A
- Fundamental
- Price
- RXRX $9.28
- IOVA $5.78
- Analyst Decision
- RXRX Buy
- IOVA Strong Buy
- Analyst Count
- RXRX 4
- IOVA 9
- Target Price
- RXRX $8.75
- IOVA $23.06
- AVG Volume (30 Days)
- RXRX 32.2M
- IOVA 7.3M
- Earning Date
- RXRX 02-28-2025
- IOVA 02-26-2025
- Dividend Yield
- RXRX N/A
- IOVA N/A
- EPS Growth
- RXRX N/A
- IOVA N/A
- EPS
- RXRX N/A
- IOVA N/A
- Revenue
- RXRX $65,184,000.00
- IOVA $90,858,000.00
- Revenue This Year
- RXRX $61.89
- IOVA $13,803.28
- Revenue Next Year
- RXRX $30.83
- IOVA $167.55
- P/E Ratio
- RXRX N/A
- IOVA N/A
- Revenue Growth
- RXRX 37.64
- IOVA 12751.20
- 52 Week Low
- RXRX $5.60
- IOVA $5.05
- 52 Week High
- RXRX $15.74
- IOVA $18.33
- Technical
- Relative Strength Index (RSI)
- RXRX 58.05
- IOVA 44.96
- Support Level
- RXRX $7.33
- IOVA $5.44
- Resistance Level
- RXRX $12.36
- IOVA $5.80
- Average True Range (ATR)
- RXRX 1.01
- IOVA 0.32
- MACD
- RXRX 0.24
- IOVA 0.08
- Stochastic Oscillator
- RXRX 43.69
- IOVA 65.77
About RXRX Recursion Pharmaceuticals Inc.
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.